Comment by hiddencost

I'm struggling to figure out what is being reported. They were mostly able to stop progression in 37% of their test cohort?

"At a data cutoff of February 1, 2023, efficacy-evaluable patients treated with petosemtamab (n = 43) experienced an overall response rate of 37.2%"

They discussed "progression free" survival, which seems to mean the condition didn't worsen.